- Home
- RNXT vs KALA Comparison
RNXT vs KALA Comparison
Compare RNXT & KALA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RNXT
- KALA
- Stock Information
- Founded
- RNXT 2012
- KALA 2009
- Country
- RNXT United States
- KALA United States
- Employees
- RNXT N/A
- KALA N/A
- Industry
- RNXT Biotechnology: Pharmaceutical Preparations
- KALA Biotechnology: Pharmaceutical Preparations
- Sector
- RNXT Health Care
- KALA Health Care
- Exchange
- RNXT Nasdaq
- KALA Nasdaq
- Market Cap
- RNXT 24.0M
- KALA 27.7M
- IPO Year
- RNXT 2021
- KALA 2017
- Fundamental
- Price
- RNXT $1.22
- KALA $5.79
- Analyst Decision
- RNXT Strong Buy
- KALA Strong Buy
- Analyst Count
- RNXT 3
- KALA 2
- Target Price
- RNXT $6.13
- KALA $16.50
- AVG Volume (30 Days)
- RNXT 26.8K
- KALA 8.0K
- Earning Date
- RNXT 11-12-2024
- KALA 11-11-2024
- Dividend Yield
- RNXT N/A
- KALA N/A
- EPS Growth
- RNXT N/A
- KALA N/A
- EPS
- RNXT N/A
- KALA N/A
- Revenue
- RNXT N/A
- KALA N/A
- Revenue This Year
- RNXT N/A
- KALA N/A
- Revenue Next Year
- RNXT N/A
- KALA N/A
- P/E Ratio
- RNXT N/A
- KALA N/A
- Revenue Growth
- RNXT N/A
- KALA N/A
- 52 Week Low
- RNXT $0.53
- KALA $4.21
- 52 Week High
- RNXT $2.35
- KALA $10.97
- Technical
- Relative Strength Index (RSI)
- RNXT 62.13
- KALA 41.97
- Support Level
- RNXT $0.98
- KALA $5.73
- Resistance Level
- RNXT $1.25
- KALA $6.20
- Average True Range (ATR)
- RNXT 0.10
- KALA 0.22
- MACD
- RNXT 0.01
- KALA 0.00
- Stochastic Oscillator
- RNXT 77.15
- KALA 12.77
About RNXT RenovoRx Inc.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.
About KALA KALA BIO Inc.
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.